◀ Back to IGF1

IGF1 — PTPRF

Text-mined interactions from Literome

Jenkins et al., Horm Res 2004 (Acromegaly...) : This study prospectively determined the effects of the depot somatostatin analogue octreotide LAR on pituitary tumour size, GH and IGF-I levels and clinical symptoms in a cohort of previously untreated patients with acromegaly
Helle et al., Eur J Cancer 2005 (Breast Neoplasms) : Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
Gołkowski et al., Przegl Lek 2006 (Acromegaly...) : CONCLUSIONS : Octreotide-LAR efficiently reduces somatomedin C and GH levels in patients with active acromegaly
Potter et al., Pituitary 2008 (Acromegaly...) : Octreotide LAR reduced GH, IGF-1 and insulin resistance index but did not alter levels of CRP and NT-pro BNP
Attia et al., Clin Adv Hematol Oncol 2008 (Carcinoma, Hepatocellular...) : To correlate the effect of octreotide long acting release (LAR) on insulin-like growth factor-I (IGF-I) and -II ( IGF-II ) with response and survival in patients with unresectable and metastatic hepatocellular carcinoma
Lima et al., Growth Horm IGF Res 2010 (Acromegaly...) : Although octreotide LAR promoted a significant decrease in the GH and IGF-I levels, it did not normalize the GH isoforms composition and suggests that the secretion of GH isoforms is equally inhibited by somatostatin analogues and that it is the disease control that normalizes the GH isoforms composition in acromegaly